Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Hoffer, G. Siggins, A. Oliver, F. Bloom (1972)
Cyclic AMP-mediated adrenergic synapses to cerebellar Purkinje cells.Advances in cyclic nucleotide research, 1
B. Martin (1986)
Cellular effects of cannabinoids.Pharmacological reviews, 38 1
B. Hoffer, G. Siggins, A. Oliver, F. Bloom (1973)
Activation of the pathway from locus coeruleus to rat cerebellar Purkinje neurons: pharmacological evidence of noradrenergic central inhibition.The Journal of pharmacology and experimental therapeutics, 184 3
Hoffer Hoffer, Siggins Siggins, Oliver Oliver, Bloom Bloom (1973)
Cyclic AMP‐mediated adrenergic synapses to cerebellar purkinje cellsJ. Pharmacol. Exp. Ther., 184
C. Hillard, A. Bloom (1984)
FURTHER STUDIES OF THE INTERACTION OF DELTA-9-TETRAHYDROCANNABINOL WITH THE BETA-ADRENERGIC RECEPTOR*
(1982)
The Rat Brain in Stereofaxic Coordinates
Hillard Hillard, Bloom Bloom (1982)
Δ 9 ‐Tetrahydrocannabinol‐induced changes in β ‐adrenergic receptor binding in mouse cerebral cortexBrain Res., 235
B. Martin, R. Balster, R. Razdan, L. Harris, W. Dewey (1981)
Behavioral comparisons of the stereoisomers of tetrahydrocannabinols.Life sciences, 29 6
Howlett Howlett (1987)
Cannabinoid inhibition of adenylate cyclase: relative activities of marihuana constituents and metabolitesNeuropharmacology, 26
Allyn Howlett (1987)
Cannabinoid inhibition of adenylate cyclase: Relative activity of constituents and metabolites of marihuanaNeuropharmacology, 26
(1989)
The Discovery of a Cannabinoid Receptor
M. Reichman, W. Nen, L. Hokin (1987)
Effects of delta 9-tetrahydrocannabinol on prostaglandin formation in brain.Molecular pharmacology, 32 5
(1985)
Outpatient cannabinoid therapy for heterogenous glaucomas: guidelines for institution and maintenance of therapy
M. Reichman, W. Nen, L. Hokin (1988)
Delta 9-tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices.Molecular pharmacology, 34 6
M. Guttman (1987)
Receptors in the Basal GangliaCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 14
L. Hollister (1986)
Health aspects of cannabis.Pharmacological reviews, 38 1
K. Seamon, J. Daly (1981)
Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein.The Journal of biological chemistry, 256 19
P. Vaysse, E. Gardner, R. Zukin (1987)
Modulation of rat brain opioid receptors by cannabinoids.The Journal of pharmacology and experimental therapeutics, 241 2
(1986)
The pharmacohistory of Cannabis sativa, in Cannabinoids as Therapeutic Agents
H. Chneiweiss, J. Glowinski, J. Prémont (1985)
Vasoactive Intestinal Polypeptide Receptors Linked to an Adenylate Cyclase, and Their Relationship with Biogenic Amine‐ and Somatostatin‐Sensitive Adenylate Cyclases on Central Neuronal and Glial Cells in Primary CulturesJournal of Neurochemistry, 44
C. Hillard, A. Bloom (1983)
Possible role of prostaglandins in the effects of the cannabinoids on adenylate cyclase activity.European journal of pharmacology, 91 1
M. Bradford (1976)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Analytical biochemistry, 72
Guttman Guttman (1987)
Receptors in the basal ganglia. Can. J. NeurolSci., 14
P. Magistretti, J. Morrison (1988)
Noradrenaline- and vasoactive intestinal peptide-containing neuronal systems in neocortex: Functional convergence with contrasting morphologyNeuroscience, 24
T. Dolby, Lewis Kleinsmith (1974)
Effects of delta 9-tetrahydrocannabinol on the levels of cyclic adenosine 3',5'-monophosphate in mouse brain.Biochemical pharmacology, 23 13
C. Borghi, S. Nicosia, A. Giachetti, S. Said (1979)
Vasoactive intestinal polypeptide (VIP) stimulates adenylate cyclase in selected areas of rat brain.Life sciences, 24 1
A. Giachetti, S. Said, R. Reynolds, F. Koniges (1977)
Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals.Proceedings of the National Academy of Sciences of the United States of America, 74 8
(1985)
Anticonvulsant effects of cannabidiol stereoisomers and analogs in rats, in Marihuana ’84
W. Devane, F. Dysarz, M. Johnson, L. Melvin, A. Howlett (1988)
Determination and characterization of a cannabinoid receptor in rat brain.Molecular pharmacology, 34 5
A. Howlett, M. Johnson, L. Melvin, G. Milne (1988)
Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.Molecular pharmacology, 33 3
A. Howlett, J. Qualy, L. Khachatrian (1986)
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.Molecular pharmacology, 29 3
A. Bloom (1984)
EFFECTS OF CANNABINOIDS ON NEUROTRANSMITTER RECEPTORS IN THE BRAIN
P. Little, D. Compton, M. Johnson, L. Melvin, B. Martin (1988)
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.The Journal of pharmacology and experimental therapeutics, 247 3
C. Brostrom, Christine Kon (1974)
An improved protein binding assay for cyclic AMP.Analytical biochemistry, 58 2
A. Howlett (1985)
Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes.Molecular pharmacology, 27 4
R. Pertwee (1988)
The central neuropharmacology of psychotropic cannabinoids.Pharmacology & therapeutics, 36 2-3
Abstract: The mechanism by which cannabinoid compounds produce their effects in the rat brain was evaluated in this investigation. Cannabinoid receptors, quantitated by (3H)CP‐55,940 binding, were found in greatest abundance in the rat cortex, cerebellum, hippocampus, and striatum, with smaller but significant binding also found in the hypothalamus, brainstem, and spinal cord. Using rat brain slice preparations, we evaluated the effect of desacetyllevonantradol on basal and forskolin‐stimulated cyclic AMP accumulation in the regions exhibiting the greatest cannabinoid receptor density. Desacetyllevonantradol (10 μM) reduced cyclic AMP levels in the hippocampus, frontal cortex, and striatum. In the cerebellum, however, the response to desacetyllevonantradol was biphasic with cyclic AMP accumulation being decreased at lower and increased at higher concentrations. Desacetyllevonantradol reduced cyclic AMP accumulation in isoproterenol‐stimulated slices in the cortex and cerebellum, but not in the hippocampus. Cells that responded to vasoactive intestinal peptide with an increase in cyclic AMP accumulation in the hippocampus and cortex also responded to desacetyllevonantradol. The modulation of cyclic AMP accumulation by desacetyllevonantradol could be attenuated following stereotaxic implantation of pertussis toxin, supporting the involvement of a G protein in the cannabinoid response in the brain. However, other actions of cannabinoid compounds may also affect the cyclic AMP levels in brain slice preparations.
Journal of Neurochemistry – Wiley
Published: Jul 1, 1990
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.